SuperSonic Imagine Announces Appointment of Michael Brock as Supervisory Board Chairman
Regulatory News:
SuperSonic Imagine (Paris:SSI) (Euronext: SSI, FR0010526814), a company specializing in ultrasound medical imaging, today
announced the appointment of Michael Brock, until now Vice-Chairman of the Supervisory Board, as Supervisory Board Chairman.
Michael Brock will replace Hermann Requardt, who has stood down in order to take up other duties preventing him from being able to
fulfil his role on the Supervisory Board.
Michael Brock states: “I am very pleased to take up the position of Chairman of the Supervisory Board of SuperSonic Imagine.
The effort made and work done following last year’s strategic refocusing are gradually starting to pay off. I am ever more
impressed by the clinical benefits provided by Aixplorer for the diagnosis of diseases of the liver and breast, as well as the
selflessness of SuperSonic Imagine’s staff in order to allow the company to become one of the most recognised names in ultrasound
medical imaging.”
Bernard Doorenbos, CEO, comments: “We are delighted to welcome Michael as Chairman of the Supervisory Board of SuperSonic
Imagine. His expertise in ultrasound imaging and selling innovative healthcare solutions are unique strengths that will support our
growth in our key markets. We would like to thank Hernmann Requardt for his commitment and the contribution he has made.”
Prior to taking up the role of Vice-Chairman of the Supervisory Board of SuperSonic Imagine, Michael Brock was Chief Executive
Officer of the Danish company BK Medical, a global leader in ultrasound imaging in the field of urology and surgery. He brings more
than 20 years leadership experience in the medical equipment market to the Chairman position.
About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The
company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that
can acquire images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this
unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™
Elastography (SWE™), UltraFast™ Doppler and more recently Angio PL.U.S – Planewave UltraSensitive™ Imaging. ShearWave Elastography
allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner.
This criteria has become an important parameter in diagnosing potentially malignant tissue or other diseased tissue. As of today,
over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of patients with a wide range of
diseases. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam, providing physicians with
exam results simultaneously and helping to increase patient throughput. The latest innovation, Angio PL.U.S, provides a new level
of microvascular imaging through significantly improved color sensitivity and spatial resolution while maintaining exceptional 2D
imaging. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets.
SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI. For more information about SuperSonic Imagine,
please go to www.supersonicimagine.com.
SuperSonic Imagine
Bernard Doorenbos, +33 6 15 66 64 68
CEO
bernard.doorenbos@supersonicimagine.com
or
NewCap
Investor Relations – EU
Pierre Laurent / Florent Alba
+33 1 44 71 98 55
supersonicimagine@newcap.fr
or
SuperSonic Imagine
Elisabeth Winter, +33 6 61 45 69 17
Finance Director, Executive VP
elisabeth.winter@supersonicimagine.com
or
Pascale Communication
Media Relations - US
Amy Phillips, +1 412 327 9499
amy@pascalecommunications.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161102006072/en/